🔥36氪•Stalecollected in 54m
SK Hynix expands cooperation in Wuxi
💡Major semiconductor firm SK Hynix pivots to AI-integrated healthcare infrastructure in China.
⚡ 30-Second TL;DR
What Changed
SK Hynix has invested over $23 billion in Wuxi across seven phases.
Why It Matters
While primarily a business expansion, it highlights the diversification of major semiconductor firms into AI-integrated healthcare services.
What To Do Next
Watch for potential cross-industry AI applications in healthcare as semiconductor firms invest in medical infrastructure.
Who should care:Enterprise & Security Teams
Key Points
- •SK Hynix has invested over $23 billion in Wuxi across seven phases.
- •The company is expanding beyond semiconductors into the life sciences and medical sectors.
- •A new international hospital project is being co-developed with local Wuxi entities.
- •The partnership aligns with high-level China-South Korea strategic cooperation goals.
🧠 Deep Insight
Web-grounded analysis with 14 cited sources.
🔑 Enhanced Key Takeaways
- •The Wuxi DRAM fab, a critical production base, successfully upgraded its process from 1z (3rd generation 10nm DRAM) to 1a (4th generation 10nm DRAM) by early 2026, circumventing US export controls by conducting the Extreme Ultraviolet (EUV) process in South Korea and finalizing production in Wuxi.
- •The Wuxi facility accounts for a substantial 30-40% of SK Hynix's total DRAM output, with a monthly capacity of 180,000-190,000 12-inch wafers, predominantly on the 1a process.
- •Beyond memory, SK Hynix's 8-inch foundry subsidiary, SK Hynix System IC, completed the relocation of its manufacturing capacity to Wuxi by 2022 and subsequently sold a 49.9% stake in this Wuxi foundry unit to China's state-owned Wuxi Industry Development Group (WIDG) for $349.3 million in May 2024, focusing on mature chips (28nm or larger).
- •The international medical complex project, initiated with a 3.8 billion yuan (approximately $579 million - $605 million) investment in 2018, includes a hospital and a medical education center co-developed with IRCAD, a France-based research and education institute, with the hospital and education center initially expected to open in 2023.
🛠️ Technical Deep Dive
- DRAM Production in Wuxi:
- Process Node: Converted from 1z (3rd generation 10nm-class DRAM) to 1a (4th generation 10nm-class DRAM).
- EUV Strategy: For 1a DRAM production, the critical EUV lithography process is performed in South Korea, and the remaining manufacturing steps are completed in the Wuxi fab due to US export restrictions on EUV equipment to China.
- Capacity: The Wuxi DRAM plant has a monthly production capacity of 180,000-190,000 12-inch wafers, with approximately 90% utilizing the 1a process.
- Foundry Operations in Wuxi (SK Hynix System IC Wuxi Solutions):
- Process Technologies: Specializes in processes ranging from 0.18um down to 90nm.
- Product Focus: Manufactures system semiconductors including BCDMOS, CMOS Image Sensors (CIS), High Voltage CMOS (HV CMOS), and MEMS processes.
- Wafer Size: Primarily produces foundational chips (28nm or larger) on 8-inch wafers.
- Strategic Production Split: SK Hynix's long-term strategy involves producing general-purpose products and legacy-process consumer DRAM in China, while concentrating advanced DRAM, such as 1c (6th generation 10nm-class) and High Bandwidth Memory (HBM), in its South Korean fabs (e.g., Icheon M14/M16, Cheongju M15X, Yongin).
🔮 Future ImplicationsAI analysis grounded in cited sources
SK Hynix will continue to strategically differentiate its Wuxi operations from its advanced Korean fabs.
US export controls and the current setup (EUV in Korea, rest in Wuxi for 1a DRAM; Wuxi foundry for mature chips) suggest a long-term strategy of producing general-purpose/legacy DRAM and foundry products in China, while focusing cutting-edge HBM and advanced DRAM in Korea.
SK Hynix's diversification into the medical sector in Wuxi will serve as a model for other semiconductor companies seeking to expand their business scope in China.
This move demonstrates a strategy to leverage local partnerships and significant investment beyond core semiconductor manufacturing, potentially opening new revenue streams and strengthening local ties amidst geopolitical complexities.
The partnership with Wuxi Industry Development Group in the foundry business will lead to increased localization of the supply chain for mature chips in China.
Selling a significant stake to a state-owned Chinese entity suggests a move towards deeper integration with the local ecosystem and potentially greater autonomy for the Wuxi foundry within China.
⏳ Timeline
2004-04
Hynix-ST joint venture construction launched in Wuxi, China.
2006
SK Hynix began DRAM production at its C2 fabrication line in Wuxi, its first 300mm wafer fab.
2018-04
SK Hynix signed an agreement to establish an international medical complex in Wuxi with an investment of approximately 3.8 billion yuan.
2019-04
SK Hynix completed the C2F expansion of its DRAM production line in Wuxi for technological migration.
2022
SK Hynix System IC completed the relocation of its 8-inch foundry manufacturing capacity from Cheongju, South Korea, to Wuxi, China.
2026-01
SK Hynix successfully converted its Wuxi DRAM fab process from 1z to 1a, enhancing performance despite US export restrictions.
📎 Sources (14)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
📰
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 36氪 ↗